Risk factors

Annovis Bio (ANVS) risk factors

Item 1A of every Annovis Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open ANVS in Gloom →
Annovis Bio's chart, financials and news, free in your browser.Open ANVS in Gloom →
  • FY2025 10-K risk factors
    72 risks6 new1 dropped7 reworded

    Annovis Bio faces critical cash runway limitations extending only into the third quarter of 2026, alongside NYSE delisting notices and patent extension efforts for buntanetap.

    Filed Mar 13, 2026
  • FY2024 10-K risk factors
    67 risks

    Annovis Bio faces substantial going concern doubt due to recurring net losses of $24.6 million in 2024 and limited cash of $10.6 million against $3.9 million in current liabilities.

    Filed Mar 21, 2025